JW Therapeutics Announces IND Approval for the Clinical Tria

JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus

/PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing...

Related Keywords

Shanghai , China , A Bristol Myers Squibb , James Li , China National Medical Products Administration , National Significant New Drug Development Program , National Medical Products Administration , Investigational New Drug , New England Journal , Nature Medicine , Nat Rev , Refractory Systemic Lupus , Juno Therapeutics , Bristol Myers Squibb , Jw Therapeutics ,